a School of Pharmacy, Monash University Malaysia , Selangor , Malaysia.
b Social and Administrative Pharmacy Department , Faculty of Pharmacy, Rangsit University , Muang , Pathumthani , Thailand.
Hum Vaccin Immunother. 2018 Feb 1;14(2):420-429. doi: 10.1080/21645515.2017.1392422. Epub 2017 Dec 15.
World Health Organization recommends oral cholera vaccine (OCV) to prevent and control cholera, but requires cost-effectiveness evidence. This review aimed to provide a critical appraisal and summary of global economic evaluation (EE) studies involving OCV to guide future EE study. Full EE studies, published from inception to December 2015, evaluating OCV against cholera disease were included. The included studies were appraised using WHO guide for standardization of EE of immunization programs. Out of 14 included studies, almost all (13/14) were in low- and middle-income countries. Most studies (11/14) evaluated mass vaccination program. Most of the studies (9/14) incorporated herd protective effect. The most common influential parameters were cholera incidence, OCV coverage, herd protection and OCV price. OCV vaccination is likely to be cost-effective when targeted at the population with high-risk of cholera and poor access to health care facilities when herd protection effect is incorporated and OCV price is low.
世界卫生组织推荐口服霍乱疫苗（OCV）来预防和控制霍乱，但需要成本效益的证据。本综述旨在对涉及 OCV 的全球经济评估（EE）研究进行批判性评估和总结，以指导未来的 EE 研究。纳入了从研究开始到 2015 年 12 月发表的，评估 OCV 预防霍乱疾病的 EE 研究。使用世卫组织免疫规划 EE 标准化指南对纳入的研究进行了评估。在纳入的 14 项研究中，几乎全部（13/14）来自中低收入国家。大多数研究（11/14）评估了大规模疫苗接种计划。大多数研究（9/14）纳入了群体保护效应。最常见的影响参数是霍乱发病率、OCV 覆盖率、群体保护和 OCV 价格。当针对霍乱高危人群和医疗设施获取能力差的人群，并考虑到群体保护效应和 OCV 价格较低时，OCV 接种可能具有成本效益。
